First human trial launches for promising new cancer pill

NCT ID NCT06004245

Recruiting now Disease control Sponsor: Vividion Therapeutics, Inc. Source: ClinicalTrials.gov ↗

Summary

This is a first-in-human study to test the safety and early effectiveness of a new oral drug called VVD-133214. It will be given alone and in combination with an existing immunotherapy (pembrolizumab) to people with advanced solid tumors that have specific genetic features known as MSI or dMMR. The main goals are to find a safe dose and see how the body processes the drug.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Alfred Hospital
ACTIVE_NOT_RECRUITING

Melbourne, Victoria, 3181, Australia
Asan Medical Center
RECRUITING

Seoul, 05505, South Korea
BCCA-Vancouver Cancer Centre
COMPLETED

Vancouver, British Columbia, V5Z 4E6, Canada
CLCC Leon Berard Lyon
COMPLETED

Lyon, 69008, France
City of Hope - Santa Clarita
RECRUITING

Valencia, California, 91355-9512, United States
City of Hope Cancer Center
ACTIVE_NOT_RECRUITING

Duarte, California, 91010, United States
Clinica Universidad de Navarra Madrid
ACTIVE_NOT_RECRUITING

Madrid, Madrid, 28027, Spain
Clinica Universitaria de Navarra
COMPLETED

Pamplona, Navarre, 31008, Spain
Duke University
COMPLETED

Durham, North Carolina, 27705, United States
Gustave Roussy
ACTIVE_NOT_RECRUITING

Villejuif, 94805, France
Hospital Clinico Universitario de Valencia
ACTIVE_NOT_RECRUITING

Valencia, Valencia, 46010, Spain
MD Anderson Cancer Center
ACTIVE_NOT_RECRUITING

Houston, Texas, 77030, United States
Norton Cancer Institute - MDC
ACTIVE_NOT_RECRUITING

Louisville, Kentucky, 40202, United States
Oklahoma University Health Sciences Center
ACTIVE_NOT_RECRUITING

Oklahoma City, Oklahoma, 73170, United States
Princess Margaret Cancer Center
ACTIVE_NOT_RECRUITING

Toronto, Ontario, M5G 2M9, Canada
Rigshospitalet
ACTIVE_NOT_RECRUITING

København Ø, 2100, Denmark
Royal Marsden Hospital (Sutton)
COMPLETED

Sutton, SM2 5PT, United Kingdom
SCRI Oncology Partners
ACTIVE_NOT_RECRUITING

Nashville, Tennessee, 37203, United States
START Madrid. Centro Integral Oncologico Clara Campal
ACTIVE_NOT_RECRUITING

Madrid, Madrid, 28050, Spain
Sarah Cannon Research Institute
ACTIVE_NOT_RECRUITING

London, W1G 6AD, United Kingdom
Seoul National University Bundang Hospital
RECRUITING

Seongnam-si, 463-707, South Korea
Seoul National University Hospital
RECRUITING

Seoul, 03080, South Korea
The Christie
ACTIVE_NOT_RECRUITING

Manchester, M20 4BX, United Kingdom
UZ Leuven Gasthuisberg
ACTIVE_NOT_RECRUITING

Leuven, 3000, Belgium
Vall d'Hebron Institute of Oncology (VHIO), Barcelona
ACTIVE_NOT_RECRUITING

Barcelona, BARCELONA, 08035, Spain

Conditions

Explore the condition pages connected to this study.

ADVANCED SOLID TUMORS